| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Isosakuranin functions through multiple mechanisms. It has been shown to reduce blood sugar levels in diabetic mice by binding to heat-shock protein 70 (HSP70), which is involved in insulin secretion. The compound exhibits anti-inflammatory activity against LPS-stimulated macrophages by decreasing PGE2 production. Isosakuranin is the direct rutinoside precursor to isosakuranetin, a potent natural TRPM3 antagonist (IC50: 50 nM), and is functionally selective over TRPM1/8 and TRPV1 at 10 μM. It blocks hydrogen peroxide-induced increases in reactive oxygen species (ROS), intracellular calcium concentration, caspase-3 activity, and JNK phosphorylation.
|
|---|---|
| ln Vitro |
In vitro, Isosakuranin exhibits anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells, with an IC50 >50 μM for PGE2 production inhibition. It protects PC12 cells from oxidative stress by blocking hydrogen peroxide-induced ROS increases, intracellular calcium elevation, caspase-3 activation, and JNK phosphorylation, while preventing decreases in catalase activity at 0.8 μM. As a precursor to isosakuranetin, it contributes to TRPM3 antagonism (IC50: 50 nM), showing 10-fold greater potency than naringenin at TRPM3 (50 vs. 500 nM). The compound demonstrates antimicrobial and cytoprotective effects in various cell-based assays.
|
| ln Vivo |
Isosakuranin has demonstrated antidiabetic activity in vivo, reducing blood sugar levels in diabetic mice by binding to HSP70, a protein involved in insulin secretion. The compound has been investigated for roles in oxidative stress regulation and immune modulation in metabolic, cardiovascular, and neurological research contexts. Its bioactivity in animal models supports its potential for studying diabetes, inflammation, and oxidative stress-related conditions. Isosakuranin is derived from natural botanical sources and has been evaluated in preclinical settings for its pharmacokinetic and pharmacodynamic properties. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Isosakuranin typically involve TRPM3 ion channel binding studies. The aglycone isosakuranetin shows potent TRPM3 antagonism with an IC50 of 50 nM, assessed using calcium flux assays in cells expressing recombinant TRPM3 channels. For anti-inflammatory activity, COX-2 or related enzyme inhibition assays may be performed. Binding to HSP70 can be evaluated using surface plasmon resonance or pull-down assays to determine affinity. Radioligand binding displacement studies may be employed to assess receptor selectivity. Assays are conducted in buffer systems optimized for each target protein, with appropriate positive and negative controls.
|
| Cell Assay |
In vitro cell-based assays for Isosakuranin are conducted in various cell lines. RAW264.7 macrophages are stimulated with LPS and treated with varying concentrations of Isosakuranin (typically 0-100 μM) to assess PGE2 production and cytokine release. PC12 cells are used to evaluate neuroprotective effects against hydrogen peroxide-induced oxidative stress. Cells are cultured in appropriate media at 37°C with 5% CO2. Following treatment, cell viability is assessed by MTT assay, ROS levels by fluorescent probes, and apoptosis markers by Western blot. IC50 values are calculated from dose-response curves. Experiments are performed in triplicate with appropriate controls.
|
| Animal Protocol |
In vivo animal studies for Isosakuranin are conducted in rodent models. For antidiabetic evaluation, diabetic mice are treated with Isosakuranin and blood glucose levels are monitored to assess the compound's ability to reduce hyperglycemia. For anti-inflammatory assessment, LPS-challenged mice may be used to evaluate the compound’s effect on inflammatory markers. Dosing is typically via oral administration or intraperitoneal injection. Animals are observed for clinical signs, and blood/tissue samples are collected at designated time points for biomarker analysis. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Isosakuranin (MW 448.4 g/mol, C22H24O10) is a glycosylated flavonoid with favorable solubility properties. It is typically soluble in DMSO and other organic solvents. As a naturally occurring glycoside, its pharmacokinetic profile involves deglycosylation to the active aglycone isosakuranetin in vivo. The compound has been investigated for oral bioavailability in preclinical studies. Its distribution and metabolism are consistent with other flavonoid glycosides, involving hepatic metabolism and potential enterohepatic circulation. The compound is stable under recommended storage conditions (powder at -20°C). Pharmacokinetic parameters such as Cmax, Tmax, and half-life would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for Isosakuranin are limited as it is a naturally occurring compound used primarily for research purposes. The compound is derived from edible botanical sources including Citrus species and Paliurus ramosissimus fruits, suggesting a favorable safety profile. In vitro studies indicate cytoprotective effects against oxidative stress rather than cytotoxicity. The compound is intended for non-human research use only. Standard safety precautions should be followed when handling. Further comprehensive toxicological evaluation would be required for therapeutic development. No significant adverse effects have been reported in the available literature.
|
| References | |
| Additional Infomation |
Isosakuranin is a flavonoid and glycoside compound. (2S)-5-hydroxy-2-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxacyclohexane-2-yl]oxy-2,3-dihydrochromene-4-one has been reported in Prunus serrulata var. pubescens, Rosa chinensis var. spontanea, and other organisms with relevant data.
Isosakuranin is a flavanone glycoside found in various Citrus species, Paliurus ramosissimus fruits, and Prunus lannesiana petals. It serves as an essential reference standard for citrus juice authenticity and debittering validation via HPLC/LC-MS. The compound is a candidate drought-tolerance biomarker for citrus rootstock screening programs. Its tasteless rutinoside isomer eliminates bitter off-notes from neohesperidoside contamination in sensory studies. Isosakuranin has applications in pharmacology, natural product chemistry, and plant stress response research. All uses are limited to research applications and not for human therapeutic use. |
| Molecular Formula |
C22H24O10
|
|---|---|
| Molecular Weight |
448.4200
|
| Exact Mass |
448.137
|
| CAS # |
491-69-0
|
| PubChem CID |
102004611
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
190 °C
|
| LogP |
0.286
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
32
|
| Complexity |
638
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
COC1=CC=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
|
| InChi Key |
KEEWIHDTSNESJZ-ZJHVPRRPSA-N
|
| InChi Code |
InChI=1S/C22H24O10/c1-29-11-4-2-10(3-5-11)15-8-14(25)18-13(24)6-12(7-16(18)31-15)30-22-21(28)20(27)19(26)17(9-23)32-22/h2-7,15,17,19-24,26-28H,8-9H2,1H3/t15-,17+,19+,20-,21+,22+/m0/s1
|
| Chemical Name |
(2S)-5-hydroxy-2-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~223.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.58 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2301 mL | 11.1503 mL | 22.3005 mL | |
| 5 mM | 0.4460 mL | 2.2301 mL | 4.4601 mL | |
| 10 mM | 0.2230 mL | 1.1150 mL | 2.2301 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
